Figure 3From: Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout Percentage of patients with immunoglobulin (Ig)M and/or IgG anti-pegloticase antibodies (Ab) over time for responders and nonresponders receiving biweekly and monthly pegloticase. Back to article page